Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
Real-world analysis of the incidence of SARS-CoV-2 infection post vaccination is important in determining the comparative effectiveness of the available vaccines. In this retrospective cohort study using deidentified administrative claims for Medicare Advantage and commercially insured individuals i...
Main Authors: | Cohen, K. (Author), Islam, N. (Author), Jarvis, M.S (Author), Sheils, N.E (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Research
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
by: Yusuke Okada, et al.
Published: (2021-09-01) -
Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01) -
Bibliometric Analysis of Pfizer-BioNTech (BNT162B2): A COVID-19 Vaccine
by: Waseem Hassan, et al.
Published: (2021-09-01) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-08-01) -
Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
by: Xuhua Xia
Published: (2021-07-01)